Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 15, 2026 · Filed Oct 16, 2026
The CEO of Aquestive Therapeutics sold $106K of Aquestive Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$105,600
Shares × reported transaction price
65 days after results of Aug 11, 2026, 19 days before results of Nov 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $4.06 on Oct 15, 2026, 38% above its 52-week low and 46% below its high, after a 23% drop over the previous 30 trading days
52-week range $2.95 (Jan 30, 2026) to $7.49 (Oct 20, 2025), 24% of the way up, from 250 adjusted closes. 30 trading days earlier: $5.24 on Sep 1, 2026. Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.7% | −0.1% | +3.8% |
Past results only. Not a forecast.
Insider filing
Traded Nov 10 · filed 2 days later
Routine share withholding; mechanical by default.
Insider buying
First insider buy since Jun 2022Traded Nov 10 · filed 2 days later
An Aquestive Therapeutics director paid $4.2K out of pocket for Aquestive Therapeutics shares.
Matthew W Davis (Officer) plans to sell ~$26K of Aquestive Therapeutics
Planned, from payEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
